Compare McCormick & Company, Incorporated (MKC) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McCormick & Company, Incorporated vs Novo Nordisk A/S — how do they compare? McCormick & Company, Incorporated trades at $44.81 (market cap $12.39B), while Novo Nordisk A/S trades at $38.64 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 13.3× McCormick & Company, Incorporated's market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold McCormick & Company, Incorporated for 67 Days and Novo Nordisk A/S for 116 Days on average.
| MKC | NVO | |
|---|---|---|
Market Cap | $12.39B | $165.31B |
Volume | 6,140,872 | 11,432,838 |
Sector | Consumer Staples | Health |
52-Week High | $71.65 | $63.98 |
52-Week Low | $44.14 | $35.29 |
Typical Hold Time | 67 Days | 116 Days |
Enterprise Value | $17.07B | $179.56B |
Dividend Yield | 4.18% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MKC trades at $45.94, up 1.52% today, with a bearish technical signal despite recent earnings beats. The company reported strong Q3 2026 results with 17% sales growth and margin expansion, though net cash flow was negative $90.2M in 2025. Valuation metrics appear attractive with P/E of 8.31 and ROE of 23.37%, while analyst consensus is mixed with 33% buy ratings.
The stock offers value potential with a $53.50 price target upside, supported by dividend payments and operational strength. Key risks include integration challenges from recent acquisitions and macroeconomic pressure on consumer spending. The technical picture suggests near-term resistance at $46-$47 levels despite fundamental strength.
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (35.35% net margin, 59.82% ROE). Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal, though the FDA extended review of its hemophilia drug. Cash flow remains positive at $10.81B for 2025, supporting dividend payments.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 17% upside to the $44.67 consensus target. However, competitive pressure from Eli Lilly's obesity drug pipeline and regulatory delays pose near-term risks. Analyst sentiment is bullish (59% buy ratings), but investors should monitor Q3 2026 earnings against the 0.753 EPS expectation for confirmation of growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
